Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$0.32 - $15.2 $137 - $6,551
-431 Reduced 0.29%
149,711 $48,000
Q1 2022

May 13, 2022

SELL
$1.59 - $3.16 $1 - $3
-1 Reduced -0.0%
150,142 $279,000
Q4 2021

Feb 11, 2022

SELL
$2.87 - $5.58 $138,322 - $268,933
-48,196 Reduced 24.3%
150,143 $430,000
Q3 2021

Nov 12, 2021

BUY
$3.43 - $5.63 $322,049 - $528,611
93,892 Added 89.89%
198,339 $1.01 Million
Q2 2021

Aug 13, 2021

SELL
$4.05 - $5.5 $229,635 - $311,850
-56,700 Reduced 35.19%
104,447 $509,000
Q1 2021

May 12, 2021

BUY
$4.73 - $8.15 $63,651 - $109,674
13,457 Added 9.11%
161,147 $821,000
Q4 2020

Feb 12, 2021

BUY
$4.92 - $30.67 $70,616 - $440,206
14,353 Added 10.76%
147,690 $726,000
Q3 2020

Nov 13, 2020

BUY
$21.66 - $38.86 $588,502 - $1.06 Million
27,170 Added 25.59%
133,337 $3.21 Million
Q2 2020

Aug 13, 2020

BUY
$25.47 - $39.69 $256,049 - $399,003
10,053 Added 10.46%
106,167 $4.12 Million
Q1 2020

May 14, 2020

BUY
$31.65 - $45.3 $277,633 - $397,371
8,772 Added 10.04%
96,114 $3.34 Million
Q4 2019

Feb 13, 2020

BUY
$18.94 - $49.53 $1.65 Million - $4.33 Million
87,342 New
87,342 $4.01 Million

Others Institutions Holding APRE

About Aprea Therapeutics, Inc.


  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.